ReviewMolecular cancer research : MCR2017
Cancer Immunotherapy: Whence and Whither.
Review in Molecular cancer research : MCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- ImmunoMet Oncogenesis: A New Concept to Understand the Molecular Drivers of Cancer.Journal of clinical medicine · 2025Review
- Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy.BioImpacts : BI · 2023Article
- The benefits of propofol on cancer treatment: Decipher its modulation code to immunocytes.Frontiers in pharmacology · 2022Review
- Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.Molecular cancer research : MCR · 2021Article
- mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?Frontiers of medicine · 2021Review
- Cellular immunotherapies for cancer.Irish journal of medical science · 2021Review
- The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity.Frontiers in immunology · 2021Review
- Tipping the Scales With Zebrafish to Understand Adaptive Tumor Immunity.Frontiers in cell and developmental biology · 2021Review
- Searching for the real function of mTOR signaling in the regulation of PD-L1 expression.Translational oncology · 2020Review
- Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.Breast cancer research : BCR · 2020Article
- Development of an intravital imaging system for the synovial tissue reveals the dynamics of CTLA-4 Ig in vivo.Scientific reports · 2020Article
- Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy.Cells · 2020Review
- Article
- Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer.Antibodies (Basel, Switzerland) · 2019Review
- Editorial: Cancer Plasticity and the Microenvironment: Implications for Immunity and Therapy Response.Frontiers in oncology · 2019Article
- Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management.Frontiers in pharmacology · 2019Review
- Kras and Tumor Immunity: Friend or Foe?Cold Spring Harbor perspectives in medicine · 2018Review
- The role of neoantigen in immune checkpoint blockade therapy.Experimental hematology & oncology · 2018Review
- Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.International journal of biological sciences · 2018Review
- Tumor-derived exosomes in colorectal cancer progression and their clinical applications.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The current concepts and practice of cancer immunotherapy evolved from classical experiments that distinguished "self" from "non-self" and the finding that humoral immunity is complemented by cellular immunity. Elucidation of the biology underlying immune checkpoints and interactions between ligands and ligand receptors that govern the immune system's ability to recognize tumor cells as foreign has led to the emergence of new strategies that mobilize the immune system to reverse this apparent tolerance. Some of these approaches have led to new therapies such as the use of mAbs to interfere with the immune checkpoint. Others have exploited molecular technologies to reengineer a subset of T cells to directly engage and kill tumor cells, particularly those of B-cell malignancies. However, before immunotherapy can become a more effective method of cancer care, there are many challenges that remain to be addressed and hurdles to overcome. Included are manipulation of tumor microenvironment (TME) to enhance T effector cell infiltration and access to the tumor, augmentation of tumor MHC expression for adequate presentation of tumor associated antigens, regulation of cytokines and their potential adverse effects, and reduced risk of secondary malignancies as a consequence of mutations generated by the various forms of genetic engineering of immune cells. Despite these challenges, the future of immunotherapy as a standard anticancer therapy is encouraging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.